

Date	Presenter	Title	Journal	Year	Vol	Page
2020/12/1	坂本	A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT: a prospective clinical cohort study	Leukemia	2020	17-Nov	Online ahead of print.
	長井	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas	Blood	2020	136(20)	2308-2318
2020/12/8	桐野	Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA	Blood	2020	136(1)	71-80
	加藤	Standardization of 18 F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma	J Clin Oncol	2020	5-Nov	Online ahead of print.
2020/12/15	渡辺	CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison	Blood Adv	2020	4(24)	6157-6168
	澤山	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	J Clin Oncol	2020	38(2)	155-165
2020/12/22	山田	Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients	Blood	2020	136(25)	2881-2892
2021/1/5	児嶋	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission	N Eng J Med	2020	383(26)	2526-2537
	安東	FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells	Cell	2020	18-Dec	Online ahead of print.
2021/1/19	新山	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia	J Clin Oncol	2020	38(1)	3626-3637
2021/1/26	宮崎	Trib1 promotes acute myeloid leukemia progression by modulating the transcriptional programs of Hoxa9	Blood	2021	137(1)	75-88
2021/2/2	藤岡	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome	Blood	2020	136(26)	3070-3081
	佐藤	Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease	N Eng J Med	2021	384(1)	11-19
2021/2/9	桐野	Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study	Blood Adv	2021	5(3)	725-736
	山田	MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial	Lancet Haematol	2021	8(2)	e110-e121
2021/2/16	長井	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells	Blood	2021	137(5)	624-636
2021/3/9	渡辺	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors	Blood Adv	2021	5(4)	975-983
	波多	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes	J Clin Oncol	2021	39(11)	1223-1233
2021/3/16	児嶋	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma	Blood	2021	137(5)	600-609
	加藤	Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma	Blood	2021	137(10)	1318-1326
2021/3/23	千綿	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study	Cancer Med	2021	10(5)	1726-1737
2021/3/30	坂本	MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism	Cancer Cell	2021	39(4)	527-547
	安東	Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias	Nat Immunol	2021	22(4)	520-529